{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:01:26Z","timestamp":1780948886992,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacl.2026.03.021","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:05:12Z","timestamp":1775181912000},"page":"1156-1165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life"],"prefix":"10.1016","volume":"20","author":[{"given":"Ghada I.","family":"Aboheimed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"AlRasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej A.","family":"Alfattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid O.","family":"Alhusayn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shog M.","family":"Alali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema A.","family":"Alkhbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-8768","authenticated-orcid":false,"given":"Dilek","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alashwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-7507","authenticated-orcid":false,"given":"Namik","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.03.021_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib2","first-page":"382","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/genes16010055","article-title":"Lipoprotein lipase: structure, function, and genetic variation","volume":"16","author":"Perera","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.jacl.2026.03.021_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib6","first-page":"1119","article-title":"Neurodegeneration in familial chylomicronemia syndrome","volume":"19","author":"Bashir","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.021_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel re--ations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.021_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.03.021_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib13","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Cefal\u00f9","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.jacl.2026.03.021_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4158\/EP-2018-0157","article-title":"Familial chylomicronemia syndrome: a clinical guide for endocrinologists","volume":"24","author":"Falko","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2026.03.021_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2026.03.021_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1527-3466.2003.tb00111.x","article-title":"Lipoprotein lipase activator NO-1886","volume":"21","author":"Yin","year":"2003","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jacl.2026.03.021_bib19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10803-009-0777-5","article-title":"Health-related quality of life and cognitive functioning from the perspective of parents of school-aged children with Asperger's Syndrome utilizing the PedsQL","volume":"39","author":"Limbers","year":"2009","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.jacl.2026.03.021_bib20","article-title":"Health-related quality of life in children with Down syndrome","volume":"121","author":"Fernandez Scotto","year":"2023","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.jacl.2026.03.021_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-7525-5-2","article-title":"Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales","volume":"5","author":"Varni","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jacl.2026.03.021_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1471-6712.2011.00889.x","article-title":"Cross-cultural validation of the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scale into Arabic language","volume":"25","author":"Arabiat","year":"2011","journal-title":"Scand J Caring Sci"},{"key":"10.1016\/j.jacl.2026.03.021_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13023-023-02927-8","article-title":"Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience","volume":"18","author":"Williams","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacl.2026.03.021_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124181","article-title":"MAFLD as a cardiovascular risk factor: an extended retrospective study with a control group","volume":"14","author":"Szymala-Pedzik","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.03.021_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119114","article-title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","volume":"403","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.021_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","article-title":"The burden of familial chylomicronemia syndrome from the patients' perspective","volume":"15","author":"Gelrud","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:36:48Z","timestamp":1780947408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1933287426000954"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.021","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}